Satellos Bioscience MSLE
NASDAQ MSLE
$9.94 -0.25 (-2.41%)
As of: Aug 21, 2026 · 11:56 AM EDT

Satellos Bioscience (MSLE) EPS (Basic) (2025 - 2026)

Satellos Bioscience (MSLE) posted quarterly EPS (Basic) of -$0.53 for Q1 2026, down 220.91% year-over-year from $0.44 in Q1 2025, and down 220.91% quarter-over-quarter from $0.44 in Q1 2025.

Satellos Bioscience (MSLE) EPS (Basic) (2025 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has reported EPS (Basic) for 2 consecutive years, with -$0.53 the latest figure, recorded in Q1 2026.

  • In Q1 2026, EPS (Basic) fell 220.91% year-over-year to -$0.53; the TTM figure through Mar 2026 stood at -$0.2 (changed N/A YoY), while the FY2025 annual figure was -$1.71, up 19.04% from the prior year.
  • EPS (Basic) declined to -$0.53 in Q1 2026 per MSLE's latest filing, from $0.44 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.44 in Q1 2025 and bottomed at -$0.53 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Vertex Pharmaceuticals 139.82 Bn 131.97 Bn 2.84 Bn 4.34
2 Regeneron Pharmaceuticals 86.70 Bn 78.71 Bn 3.93 Bn 12.62
3 Argenx Se 65.27 Bn 60.09 Bn 1.37 Bn 7.59
4 Moderna 59.18 Bn 54.04 Bn 52.00 Mn -1.96
5 BeOne Medicines 42.11 Bn 37.01 Bn 1.53 Bn 2.12
6 Alnylam Pharmaceuticals 31.80 Bn 28.49 Bn 992.69 Mn 1.23
7 BioNTech SE 28.14 Bn 9.75 Bn 668.28 Mn -0.72
8 Insmed 27.53 Bn 26.37 Bn 358.27 Mn -0.06
9 Royalty Pharma 27.26 Bn 26.42 Bn - 0.18
10 Satellos Bioscience 207.06 Mn 207.06 Mn - -0.56

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.53
Mar 31, 2025 0.44